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Summary To obtain suitable cell lines for the immortalisation of human lymphocytes, we constructed a
heteromyeloma between the murine myeloma Ag8 and human lymphocytes from a highly malignant polymor-
phic, centroblastic B-cell lymphoma. The thioguanine-resistant and HAT-sensitive heteromyeloma HAB-1
neither secretes nor contains cytoplasmatic immunoglobulins, the cells being EBV negative but positively
stained for HLA-BC and the human proliferation marker Ki-67. The karyotype consists of about 50 murine
and 20 human chromosomes. The HAB-l cells grow in suspension and have a doubling rate of about 25-30 h.
In fusion experiments with spleen cells from stomach carcinoma patients HAB-1 cells show a 5-7 times higher
fusion efficiency than murine Ag8 cells or another heteromyeloma SPM4-0 and give stable antibody producing
products. The cell line will be made available to interested scientists.
For the production of human monoclonal antibodies several
experimental systems have been used to immortalise human
B-cells Human - mouse hybrids are genetically unstable,
resulting in a rapid loss of antibody production (Croce et al.,
1980; Cote et al., 1983; Gigliotti et al., 1984;). Several
experiments have been performed with human myeloma and
lymphoblastoid cells (Olsson & Kaplan, 1980; Abrams et al.,
1983; Ritts et al., 1983; Satoh et al., 1983; Strike et al., 1984;
Glassy et al., 1983; Borrebaek et al., 1987), but there is still a
need for suitable malignant lines.
Transformation of human lymphocytes by EBV or somatic
hybridisation of EBV-transformed lymphocytes with myeloid
cells is still the most commonly used method for immortalis-
ing human lymphocytes (Kozbor & Roder, 1981; Cote et at.,
1984; Yamaguchi et al., 1987; Furukawa et al., 1988). The
major disadvantage of this technique is the possible con-
tamination of hybridoma supernatants with viral products.
The most promising approach to obtain stable human
monoclonal antibodies producing B-lymphocytes was
originally described by Teng et al. (1983). The authors con-
structed a heteromyeloma between a human lymphoblastoid
cell line (FU 266) and a murine myeloma (Ag8) and isolated
a non-secreting, TG-resistant and HAT-sensitive cell line
PSV2.Neo. These cells gave greater numbers of stable
hybrids when fused with lymphocytes than did mouse cells
alone. Ostberg and Pursch (1983) produced a heteromyeloma
fusion partner from the mouse myeloma line SP2/0 and
normal human peripheral blood lymphocytes (PBLs). They
fused this heteromyeloma with lymphocytes from immunised
donors and established hybridomas which showed stable
antibody production in long-term and mass culture. Several
other laboratories have used such heteromyelomas between
murine myelomas and human myelomas, normal human B-
lymphocytes or B-lymphoma cells for production of human
antibodies (Foung et al., 1984; Yamaura et al., 1985; Teng et
al., 1985; Ichimori et al., 1985; Caroll et al., 1986; Martin et
al., 1988; Grunow et al., 1988; Vollmers et al., 1989). Some
of the heteromyeloma products were stable for 6 months or
longer without intensive recloning procedures, but only few
of these fusion partners are available. We describe in
this paper a new genetically stable human-mouse
heteromyeloma, HAB-1, which was produced by somatic
hybridisation of murine Ag8 myeloma cells with human lym-
phocytes from a patient with a B-cell lymphoma. The cell
line has ideal growth and fusion characteristics and has been
successfully used for the long-term production of human
monoclonal antibodies against stomach carcinoma cells.
Materials and methods
Cells andculture conditions
The non-secreting HAT (hypoxanthine-aminopterin-
thymidine) sensitive heteromyeloma HAB-1 derived from
hybridisation of murine Ag8 myeloma cells with lymph node
cells from a patient with a highly malignant centroblastic
B-cell lymphoma. Selected hybrids were exposed once to
6-thioguanine (5 lAg ml-') and growing clones were tested for
HAT-sensitivity. Established cells were maintained in RPMI-
1640 with 10% FCS (fetal calf serum) and 1% penicillin/
streptomycin. Lymph nodes and spleens obtained from
stomach carcinomas patients during surgery were prepared
by mechanical means. Cell suspensions were either incubated
in culture medium before cell fusion or stored in liquid
nitrogen until 24 h before hybridisation.
For growth kinetics, 2 x 105 living cells were plated on
24-well culture plates and counted every day. Doubling time
was determined in logarithmic growth phase.
Somatic hybridisations
Lymph node or spleen cells from stomach carcinoma patients
were fused at a ratio of 1:1 with HAB-l and SPM4-0 (kindly
provided by Hoffman LaRoche, Switzerland) or 1:5 and 1:10
with Ag8 cells using 40% polyethyleneglycol 1500 (Sigma,
FRG). Hybridomas were cultured in RPMI-1640 containing
10% FCS and HAT supplement. After 4-6 weeks the super-
natants were screened for antibody production in an enzyme-
linked immunosorbent assay (ELISA). Positive clones were
then tested in binding assays on tumour cells and cloned by
limiting dilution using irradiated nude mouse lymphocytes as
feeder layers.
Enzyme-linked immunosorbent assay (ELISA)
Human monoclonal antibodies were screened by an ELISA
procedure according to Vollmers et al. (1989) with minor
modifications. Briefly, plastic plates were pre-coated over-
night at 4°C with rabbit-anti-human-Ig antibodies
(Dakopatts, Denmark) diluted 1:2,000 in PBS (phosphate
buffered saline). Non-specific binding sites on the plastic were
blocked by treatment with 0.1 M borate buffer (pH 8.2) con-
taining 1% BSA (bovine serum albumin) for 1 h at 20°C.
Plates were washed twice with borate buffer and incubated
with hybridoma supernatant for 60 min at 37°C. Plates were
washed 2-5 times with borate buffer and then incubated with
peroxidase-conjugated rabbit immunoglobulin to human Ig
(Dakopatts, Denmark) diluted 1:1,000 in PBS for 30min at
37'C. Plates were washed twice with borate buffer, followed
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by two washing steps with 0.3 M citrate phosphate buffer and
subsequent incubation with substrate (0.03%
orthophenylene-diamine and 0.02% hydrogen peroxidase in
citrate buffer). The absorption was recorded at 492 nm in an
ELISA reader (FlowLab, FRG).
Immunoperoxidase staining on cells
Cytospin preparations (5,000 cells per slide) were fixed with
acetone washed three times with Tris buffer (pH 7.4) and
incubated with diagnostic antibodies, diluted in Tris contain-
ing 0.5% BSA, for 30 min at RT. Slides were washed twice
with Tris and incubated with peroxidase-coupled rabbit
antibodies to mouse-Ig (Dakopatts, Denmark) diluted 1:50 in
PBS containing 30% AB-Rh-positive human serum for
30 min at RT. Slides were washed again twice with Tris
(ph 7.4) and once the Tris (pH 7.6) and then incubated with
substrate (0.006% diaminiobenzidine and 0.015% hydrogen
peroxide) for 10min. The cells were briefly counterstained
with haematoxylin.
Immunofluorescence
Cells grown to subconfluence on microscope slides during an
overnight incubation at 37°C were washed with PBS and
fixed with methanol/acetone (1:1) for Omin at RT. The
fixed cells were washed three times with PBS, incubated with
hybridoma supernatants for 45 min at 37°C, washed again
with PBS and incubated with FITC-coupled rabbit
antibodies to human IgM, diluted 1:20 (Dakopatts, Den-
mark) for 45 min at 37°C. Slides were mounted in PBS/
glycerol (1:9).
Karyotype analysis
Growing cells were incubated for 60 min with 10l ml1'
colcemid (Gibco, FRG) at 37°C. The cells were then tryp-
sinised, pelleted and incubated with 15 ml of warm 0.8%
sodium citrate/0.075 M KCI solution for 15 min at 37°C.
Cells were centrifuged, fixed with methanol/acetic acid (4:1)
and stored at - 20°C. For G-banding experiments, pelleted
cells were dropped on cold slides and dried for one week at
RT. The slides were then incubated in PBS (50ml, containing
175 ,lA Bacto-Trypsin) for 75 s, then washed with PBS for
75 s and stained with 7% Giemsa solution for 8 min (Sea-
bright, 1971).
Results
Construction and characterisation ofthe heteromyeloma
HAB-1
Heteromyeloma cell lines were derived from fusions of lymph
node cells from a patient with a highly malignant polymor-
phic centroblastic B cell lymphoma to the non-secreting
murine myeloma Ag8. Growing heteromyelomas were tested
for secreted and cytoplasmic antibodies and immunoglobulin
(Ig) negative cells were re-cloned by exposure to 5fig ml-'
TG. Several TG-mutants could be isolated and were subse-
quently tested for HAT-sensitivity. The Ig-negative and
HAT-sensitive heteromyeloma HAB-1 was selected for fur-
ther investigations for mainly two reasons: the cells die after
a relatively short time in HAT-medium (after 3-4 days, data
not shown) and show a rapid proliferation in normal culture
medium. The cells grow in solution, double every 25-30 h
and reach a maximal density of about 2 x 106 cells ml-
(Figure 1).
By using immunohistochemical staining procedures the
phenotype of HAB-1 was determined and compared with the
primary B-lymphoma 10030, used for construction of HAB-1
and a HAB-1 heteromyeloma fusion product, 70/5 (IgA, k).
Table I shows that the heterogeneous lymphoma cell popula-
tion is positively stained for T-cells (CD3), T-subsets (CD4,
CD5) and NK-cells (CD57). When tested for B-cell markers,
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Figure 1 Growth kinetics. Cells were seeded on 24 tissue culture
plates, grown for one week and counted every day: (@) HAB-1;
(A) Ag8; (0) SPM4-0.
Table I Immunophenotyping of the parental lymphoma 10030, the
heteromyeloma HAB-I and the fusion product 70/5
Staining on
Marker 10030 HAB-J 70/5
CD3 + _
CD4 +
CD5 + +
CD8
CD57 +
CD19 - -
CD21 - - _
CD22 + + _ _
IgG - _ _
IgM + + _ _
IgA - - + +
kappa + + - + +
lambda
HLA-BC + + + + + +
HLA-DR + + - -
Ki67 + + +
EBNA +
CD22 (B-subset) is positive, while CD19 and CD21 are
negative. A strong expression of IgM,k, HLA-BC and HLA-
DR is observed. The lymphoma cells are also positive for the
proliferation marker Ki-67 and the EBV-product EBNA.
Compared to this the heteromyeloma HAB-1 is only positive
for HLA-BC and Ki-67, while all other markers are lost. The
HAB-1 fusion product 70/5, which secretes an IgA (k), has
the same characteristics. From these data, one cannot deter-
mine from which type of cell, lymphoma cell or proliferating
normal lymphocyte, the heteromyeloma derived.
To investigate the karyotype of the heteromyeloma HAB-1
G-banding experiments were performed. Figure 2a shows
that the Ag8 cells have on average 50 acrocentric and two
metacentric chromosomes, whereas HAB-1 has around
65-70 chromosomes (Figure 2b). Consistently, in most
metaphases, followed over a longer period of time in culture,
chromosomes 6; 13, 14, 15; 16, 17, 18 and 21, 22 are always
retained in the heteromyeloma (Figure 2c). No significant
change in the number of human chromosomes could be
observed after one year of cultivation.
In freshly re-cloned HAB-1 fusion products 25-30 human
chromosomes can be identified and after 12 months in cul-
ture there are still around 20 (not shown).
Somatic hybridisations with the heteromyeloma HAB-J
To investigate the fusion characteristics of the
heteromyeloma HAB-1, several hybridisations were done
with spleen cells from stomach carcinoma patients and theHETEROMYELOMA FOR PRODUCTION OF HUMAN ANTIBODIES 597
HAB-l is 5-7 times higher than that obtained with SPM4-0
or Ag8. The number ofIg-producing clones is similar with all
three fusion partners, i.e. between 20 and 26%.
To determine the stability of the fusion products, the
primary cells were re-cloned once and the supernatants of the
reclones were tested every two weeks for antibody produc-
tion. The hybrids generated with Ag8 usually lose antibody
activity after 2 months, whereas the heteromyeloma products
show a much longer stability, some having been in culture
now for more than 2 years. Using HAB-l as fusion partner,
several human monoclonal antibodies which react with the
autologous tumour cells could be isolated from stomach
carcinoma patients. As an example, Figure 3a shows a
fluorescence staining with the antibody 94/51 (IgM) on cul-
tured stomach adenocarcinoma cells.
Discussion
Rapid proliferation and genetic stability of fusion partners
and products is most important for successful long-term
production of human monoclonal antibodies. We described
in a recent study the establishment of human monoclonal
antibodies from patients with signet ring carcinomas of the
stomach by using the heteromyeloma SPM4-0 as source of
parental cells (Vollmers et al., 1989). We obtained hybrid
lines, which have been stable now for more than two years in
culture, growing in mass culture and serum free medium. The
cell line SPM4-0 was produced by fusion of PBLs with the
Figure 2 Cytogenetic analysis. Chromosome preparations and
G-banding were performed as described in Material and methods:
a, metaphase of murine myeloma Ag8; b, metaphase of
heteromyeloma HAB-1; c, analysed human chromosomes of
HAB-I .
results were compared with those obtained by fusions with
Ag8 and SPM4-0. Most studies were performed in parallel
with the same source of lymphocytes. The data from 57
hybridisations are shown in Table II. The mean growth rate
of hybrids developed with HAB-1 was around 70%, with
SPM4-0 and Ag8 only about 30%. The fusion frequency of
Figure 3 Immunofluorescence on tumour cells. Staining on
autologous stomach carcinoma cells: a, humAb 94/51; b, control
Table II Fusion results
Lymphocyte Hybrid Fusion Ig Stability
Fusion No. source growth frequency production (months)
partner fusions (%) x 10-6 (%)
HAB-1 10 spleen 70 4.5 25 > 12
SPM4-0 37 spleen 37 0.7 20 >24
Ag-8 10 spleen 31 1.0 26 <3
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murine myeloma Ag8. Apart from excellent stability the cells
show good cloning efficiency. The major disadvantage of the
heteromyeloma cell line is that the cells grow adherently and
have to be trypsinised. In addition, they grow slowly and do
not reach high cellular density. To produce a heteromyeloma
with a similar stability but better growth characteristics, we
fused murine Ag8 cells to lymph node cells from a patient
with a highly proliferating malignant B-cell lymphoma. A
similar approach was described by Caroll et al. (1986), who
made heteromyelomas between NS-1 cells and lymphoid cells
from a patient with a nodular lymphoma. They obtained
heteromyelomas with excellent fusion and growth characteris-
tics, but the fusion products showed only a low stability (<2
months), most likely due to genetic instability.
The stability of a heteromyeloma is surely influenced by
the number of human chromosomes in the parental
heteromyeloma. Grunow et al. (1988) described a
heteromyeloma named CB-F7 with good growth and fusion
characteristics. Chromosomal analysis of this cell line
revealed around 70 murine and only three human
chromosomes. In hybridomas between CB-F7 and human
PBLs only 5-10 human chromosomes were observed. The
hybrids showed stable Ig-production up to 6 months under
normal growth conditions, but for long-term cultures the
cells had to be re-cloned 2-4 times.
The heteromyeloma HAB-1 was therefore selected for its
high proliferation rate and high number and low segregation
of human chromosomes in the parental cell over a long
period of time. G-banding experiments with HAB-1 revealed
about 15-20 huan chromosomes, which are still found after
1 year in cell culture. A preferential retention was found for
chromosomes 6, 11, 13, 14, 15, 16, 17, 18, 21 and 22. No
significant change in the karyotype could be observed after 1
year of cultivation. Cytogenetic studies with HAB-1 fusion
products gave similar results. Freshly re-cloned cells had
about 75-85 chromosomes (50 mouse and 25-35 human)
and still around 70 chromosomes even after 1 year in culture.
The described characteristics together with the facts that
HAB-1 is negative for EBV and does not produce and secrete
its own immunoglobulins make the cells an ideal fusion
partner for human lymphocytes.
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